Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101 for Oropharyngeal Cancer
This trial is studying PDS0101, a vaccine made from specific peptides, either alone or in combination with pembrolizumab, to see how well it works in treating patients with human papillomavirus-associated oropharynx cancer that has spread to nearby tissue or lymph nodes.
- Oropharyngeal Cancer
- Oropharyngeal Carcinoma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
What is the current enrollment capacity for this medical experiment?
"Affirmative. Clinicaltrials.gov's records show that the trial was first made public on March 7th 2022 and has been actively searching for participants since then; it is currently seeking 24 volunteers from 1 medical centre."
Is enrollment still open for this research project?
"According to the information provided by clinicaltrials.gov, this medical trial is presently enrolling patients with its initial posting on March 7th 2022 and a recent update taking place on March 11th 2022."